精品国产精品免费在线观看|亚洲一级高清在线观看|亚洲乱码尤物193yw|亚洲综合狠狠99婷婷

      Pharmacoepidemiology And Drug Safety
      • 數(shù)據(jù)庫(kù)收錄SCIE
      • 創(chuàng)刊年份1992年
      • 年發(fā)文量137
      • H-index85

      Pharmacoepidemiology And Drug Safety

      期刊中文名:藥物流行病學(xué)和藥物安全ISSN:1053-8569E-ISSN:1099-1557

      該雜志國(guó)際簡(jiǎn)稱:PHARMACOEPIDEM DR S,是由出版商John Wiley and Sons Ltd出版的一本致力于發(fā)布醫(yī)學(xué)研究新成果的的專業(yè)學(xué)術(shù)期刊。該雜志以PHARMACOLOGY & PHARMACY研究為重點(diǎn),主要發(fā)表刊登有創(chuàng)見(jiàn)的學(xué)術(shù)論文文章、行業(yè)最新科研成果,扼要報(bào)道階段性研究成果和重要研究工作的最新進(jìn)展,選載對(duì)學(xué)科發(fā)展起指導(dǎo)作用的綜述與專論,促進(jìn)學(xué)術(shù)發(fā)展,為廣大讀者服務(wù)。該刊是一本國(guó)際優(yōu)秀雜志,在國(guó)際上有很高的學(xué)術(shù)影響力。

      基本信息:
      期刊簡(jiǎn)稱:PHARMACOEPIDEM DR S
      是否OA:未開(kāi)放
      是否預(yù)警:
      Gold OA文章占比:31.52%
      出版信息:
      出版地區(qū):ENGLAND
      出版周期:Bimonthly
      出版語(yǔ)言:English
      出版商:John Wiley and Sons Ltd
      評(píng)價(jià)信息:
      中科院分區(qū):4區(qū)
      JCR分區(qū):Q2
      影響因子:2.4
      CiteScore:4.8
      雜志介紹 中科院JCR分區(qū) JCR分區(qū) CiteScore 投稿經(jīng)驗(yàn)

      雜志介紹

      Pharmacoepidemiology And Drug Safety雜志介紹

      《Pharmacoepidemiology And Drug Safety》是一本以English為主的未開(kāi)放獲取國(guó)際優(yōu)秀期刊,中文名稱藥物流行病學(xué)和藥物安全,本刊主要出版、報(bào)道醫(yī)學(xué)-PHARMACOLOGY & PHARMACY領(lǐng)域的研究動(dòng)態(tài)以及在該領(lǐng)域取得的各方面的經(jīng)驗(yàn)和科研成果,介紹該領(lǐng)域有關(guān)本專業(yè)的最新進(jìn)展,探討行業(yè)發(fā)展的思路和方法,以促進(jìn)學(xué)術(shù)信息交流,提高行業(yè)發(fā)展。該刊已被國(guó)際權(quán)威數(shù)據(jù)庫(kù)SCIE收錄,為該領(lǐng)域相關(guān)學(xué)科的發(fā)展起到了良好的推動(dòng)作用,也得到了本專業(yè)人員的廣泛認(rèn)可。該刊最新影響因子為2.4,最新CiteScore 指數(shù)為4.8。

      本刊近期中國(guó)學(xué)者發(fā)表的論文主要有:

      • Detection of drug safety signal of drug-induced neutropenia and agranulocytosis in all-aged patients using electronic medical records

        Author: Sun, Cuicui; Zhao, Lixia; Yuan, Yujie; Xiang, Yanxiao; Liu, Anchang

      • More extreme duplication in FDA Adverse Event Reporting System detected by literature reference normalization and fuzzy string matching

        Author: Hung, Eric; Hauben, Manfred; Essex, Henry; Zou, Chen; Bright, Steve

      • A systematic review and meta-analysis of observational studies of the association between the use of incretin-based therapies and the risk of pancreatic cancer

        Author: Hidayat, Khemayanto; Zhou, Ying-Yi; Du, Hong-Zhen; Qin, Li-Qiang; Shi, Bi-Min; Li, Zeng-Ning

      • Prescribed anti-glaucoma medication consumption and road traffic crash

        Author: Lu, Li; Contrand, Benjamin; Schweitzer, Cedric; Gadegbeku, Blandine; Delcourt, Cecile; Lagarde, Emmanuel

      英文介紹

      Pharmacoepidemiology And Drug Safety雜志英文介紹

      The aim of Pharmacoepidemiology and Drug Safety is to provide an international forum for the communication and evaluation of data, methods and opinion in the discipline of pharmacoepidemiology. The Journal publishes peer-reviewed reports of original research, invited reviews and a variety of guest editorials and commentaries embracing scientific, medical, statistical, legal and economic aspects of pharmacoepidemiology and post-marketing surveillance of drug safety. Appropriate material in these categories may also be considered for publication as a Brief Report.

      Particular areas of interest include:

      design, analysis, results, and interpretation of studies looking at the benefit or safety of specific pharmaceuticals, biologics, or medical devices, including studies in pharmacovigilance, postmarketing surveillance, pharmacoeconomics, patient safety, molecular pharmacoepidemiology, or any other study within the broad field of pharmacoepidemiology;

      comparative effectiveness research relating to pharmaceuticals, biologics, and medical devices. Comparative effectiveness research is the generation and synthesis of evidence that compares the benefits and harms of alternative methods to prevent, diagnose, treat, and monitor a clinical condition, as these methods are truly used in the real world;

      methodologic contributions of relevance to pharmacoepidemiology, whether original contributions, reviews of existing methods, or tutorials for how to apply the methods of pharmacoepidemiology;

      assessments of harm versus benefit in drug therapy;

      patterns of drug utilization;

      relationships between pharmacoepidemiology and the formulation and interpretation of regulatory guidelines;

      evaluations of risk management plans and programmes relating to pharmaceuticals, biologics and medical devices.

      中科院SCI分區(qū)

      Pharmacoepidemiology And Drug Safety雜志中科院分區(qū)信息

      2023年12月升級(jí)版
      綜述:
      TOP期刊:
      大類:醫(yī)學(xué) 4區(qū)
      小類:

      PHARMACOLOGY & PHARMACY
      藥學(xué) 4區(qū)

      PUBLIC, ENVIRONMENTAL & OCCUPATIONAL HEALTH
      公共衛(wèi)生、環(huán)境衛(wèi)生與職業(yè)衛(wèi)生 4區(qū)

      2022年12月升級(jí)版
      綜述:
      TOP期刊:
      大類:醫(yī)學(xué) 4區(qū)
      小類:

      PUBLIC, ENVIRONMENTAL & OCCUPATIONAL HEALTH
      公共衛(wèi)生、環(huán)境衛(wèi)生與職業(yè)衛(wèi)生 3區(qū)

      PHARMACOLOGY & PHARMACY
      藥學(xué) 4區(qū)

      2021年12月舊的升級(jí)版
      綜述:
      TOP期刊:
      大類:醫(yī)學(xué) 4區(qū)
      小類:

      PUBLIC, ENVIRONMENTAL & OCCUPATIONAL HEALTH
      公共衛(wèi)生、環(huán)境衛(wèi)生與職業(yè)衛(wèi)生 3區(qū)

      PHARMACOLOGY & PHARMACY
      藥學(xué) 4區(qū)

      2021年12月基礎(chǔ)版
      綜述:
      TOP期刊:
      大類:醫(yī)學(xué) 3區(qū)
      小類:

      PHARMACOLOGY & PHARMACY
      藥學(xué) 3區(qū)

      PUBLIC, ENVIRONMENTAL & OCCUPATIONAL HEALTH
      公共衛(wèi)生、環(huán)境衛(wèi)生與職業(yè)衛(wèi)生 3區(qū)

      2021年12月升級(jí)版
      綜述:
      TOP期刊:
      大類:醫(yī)學(xué) 4區(qū)
      小類:

      PUBLIC, ENVIRONMENTAL & OCCUPATIONAL HEALTH
      公共衛(wèi)生、環(huán)境衛(wèi)生與職業(yè)衛(wèi)生 3區(qū)

      PHARMACOLOGY & PHARMACY
      藥學(xué) 4區(qū)

      2020年12月舊的升級(jí)版
      綜述:
      TOP期刊:
      大類:醫(yī)學(xué) 3區(qū)
      小類:

      PHARMACOLOGY & PHARMACY
      藥學(xué) 3區(qū)

      PUBLIC, ENVIRONMENTAL & OCCUPATIONAL HEALTH
      公共衛(wèi)生、環(huán)境衛(wèi)生與職業(yè)衛(wèi)生 3區(qū)

      中科院SCI分區(qū):是中國(guó)科學(xué)院文獻(xiàn)情報(bào)中心科學(xué)計(jì)量中心的科學(xué)研究成果。期刊分區(qū)表自2004年開(kāi)始發(fā)布,延續(xù)至今;2019年推出升級(jí)版,實(shí)現(xiàn)基礎(chǔ)版、升級(jí)版并存過(guò)渡,2022年只發(fā)布升級(jí)版,期刊分區(qū)表數(shù)據(jù)每年底發(fā)布。 中科院分區(qū)為4個(gè)區(qū)。中科院分區(qū)采用刊物前3年影響因子平均值進(jìn)行分區(qū),即前5%為該類1區(qū),6%~20%為2區(qū)、21%~50%為3區(qū),其余的為4區(qū)。1區(qū)和2區(qū)雜志很少,雜志質(zhì)量相對(duì)也高,基本都是本領(lǐng)域的頂級(jí)期刊。

      JCR分區(qū)(2023-2024年最新版)

      Pharmacoepidemiology And Drug Safety雜志 JCR分區(qū)信息

      按JIF指標(biāo)學(xué)科分區(qū)
      學(xué)科:PHARMACOLOGY & PHARMACY
      收錄子集:SCIE
      分區(qū):Q3
      排名:188 / 354
      百分位:

      47%

      學(xué)科:PUBLIC, ENVIRONMENTAL & OCCUPATIONAL HEALTH
      收錄子集:SCIE
      分區(qū):Q2
      排名:163 / 403
      百分位:

      59.7%

      按JCI指標(biāo)學(xué)科分區(qū)
      學(xué)科:PHARMACOLOGY & PHARMACY
      收錄子集:SCIE
      分區(qū):Q3
      排名:192 / 354
      百分位:

      45.9%

      學(xué)科:PUBLIC, ENVIRONMENTAL & OCCUPATIONAL HEALTH
      收錄子集:SCIE
      分區(qū):Q3
      排名:215 / 403
      百分位:

      46.77%

      JCR分區(qū):JCR分區(qū)來(lái)自科睿唯安公司,JCR是一個(gè)獨(dú)特的多學(xué)科期刊評(píng)價(jià)工具,為唯一提供基于引文數(shù)據(jù)的統(tǒng)計(jì)信息的期刊評(píng)價(jià)資源。每年發(fā)布的JCR分區(qū),設(shè)置了254個(gè)具體學(xué)科。JCR分區(qū)根據(jù)每個(gè)學(xué)科分類按照期刊當(dāng)年的影響因子高低將期刊平均分為4個(gè)區(qū),分別為Q1、Q2、Q3和Q4,各占25%。JCR分區(qū)中期刊的數(shù)量是均勻分為四個(gè)部分的。

      CiteScore 評(píng)價(jià)數(shù)據(jù)(2024年最新版)

      Pharmacoepidemiology And Drug Safety雜志CiteScore 評(píng)價(jià)數(shù)據(jù)

      • CiteScore 值:4.8
      • SJR:1.106
      • SNIP:1
      學(xué)科類別 分區(qū) 排名 百分位
      大類:Medicine 小類:Pharmacology (medical) Q2 105 / 272

      61%

      大類:Medicine 小類:Epidemiology Q2 63 / 148

      57%

      歷年影響因子和期刊自引率

      投稿經(jīng)驗(yàn)

      Pharmacoepidemiology And Drug Safety雜志投稿經(jīng)驗(yàn)

      該雜志是一本國(guó)際優(yōu)秀雜志,在國(guó)際上有較高的學(xué)術(shù)影響力,行業(yè)關(guān)注度很高,已被國(guó)際權(quán)威數(shù)據(jù)庫(kù)SCIE收錄,該雜志在PHARMACOLOGY & PHARMACY綜合專業(yè)領(lǐng)域?qū)I(yè)度認(rèn)可很高,對(duì)稿件內(nèi)容的創(chuàng)新性和學(xué)術(shù)性要求很高,作為一本國(guó)際優(yōu)秀雜志,一般投稿過(guò)審時(shí)間都較長(zhǎng),投稿過(guò)審時(shí)間平均 約3月 ,如果想投稿該刊要做好時(shí)間安排。版面費(fèi)不祥。該雜志近兩年未被列入預(yù)警名單,建議您投稿。如您想了解更多投稿政策及投稿方案,請(qǐng)咨詢客服。

      免責(zé)聲明

      若用戶需要出版服務(wù),請(qǐng)聯(lián)系出版商:JOHN WILEY & SONS LTD, THE ATRIUM, SOUTHERN GATE, CHICHESTER, ENGLAND, W SUSSEX, PO19 8SQ。